Previous Close | 6.05 |
Open | 6.10 |
Bid | 6.03 x 900 |
Ask | 6.04 x 1000 |
Day's Range | 5.81 - 6.13 |
52 Week Range | 1.93 - 8.56 |
Volume | 680,188 |
Avg. Volume | 2,028,377 |
Market Cap | 512.033M |
Beta (5Y Monthly) | 1.11 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The drop came after Sarepta Therapeutics (NASDAQ: SRPT) reported disappointing clinical results for experimental gene therapy SRP-9001 in treating rare genetic disease Duchenne muscular dystrophy (DMD). Sarepta's problem was that SRP-9001 didn't meet the primary functional endpoint of its clinical study. Just because SRP-9001 failed in a clinical study doesn't necessarily mean that SGT-001 will.
Ultragenyx (RARE), which has a strong pipeline, receives a few approvals for its products in 2020.
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today